1. Home
  2. ISPC vs OGEN Comparison

ISPC vs OGEN Comparison

Compare ISPC & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iSpecimen Inc.

ISPC

iSpecimen Inc.

BUY

Current Price

$0.92

Market Cap

2.6M

Sector

Health Care

ML Signal

BUY

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.45

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISPC
OGEN
Founded
2009
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
2.2M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
ISPC
OGEN
Price
$0.92
$0.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 104.7K
22.6K
Earning Date
11-16-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 87.03
N/A
EPS
N/A
★ N/A
Revenue
★ $1,928,998.00
N/A
Revenue This Year
$638.10
N/A
Revenue Next Year
$17.50
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.91
$0.43
52 Week High
$115.00
$1.45

Technical Indicators

Market Signals
Indicator
ISPC
OGEN
Relative Strength Index (RSI) 23.43 37.01
Support Level N/A N/A
Resistance Level $1.15 $0.59
Average True Range (ATR) 0.07 0.02
MACD 0.00 -0.00
Stochastic Oscillator 2.94 0.00

Price Performance

Historical Comparison
ISPC
OGEN

About ISPC iSpecimen Inc.

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: